EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Laurus Labs's enterprise value is ₹261,926 Mil.
Laurus Labs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₹8,038 Mil. Therefore, Laurus Labs's EV-to-EBITDA for today is 32.58.
The historical rank and industry rank for Laurus Labs's EV-to-EBITDA or its related term are showing as below:
BOM:540222'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3 Med: 14.68 Max: 33.2
Current: 32.59
During the past 11 years, the highest EV-to-EBITDA of Laurus Labs was 33.20. The lowest was 7.30. And the median was 14.68.
BOM:540222's EV-to-EBITDA is ranked worse than 83.64% of 715
companies
in the Drug Manufacturers industry
Industry Median: 14.47
vs BOM:540222: 32.59
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Laurus Labs EV-to-EBITDA Historical Data
The historical data trend for Laurus Labs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Laurus Labs's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laurus Labs's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Laurus Labs's EV-to-EBITDA falls into.
Laurus Labs EV-to-EBITDA Calculation
Laurus Labs's EV-to-EBITDA for today is calculated as:
Laurus Labs's current Enterprise Value is ₹261,926 Mil.
Laurus Labs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,038 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laurus Labs (BOM:540222) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Laurus Labs's PE Ratio for today is calculated as:
Laurus Labs's share price for today is ₹440.95.
Laurus Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2.970.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Laurus Labs's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:540222 has been successfully added to your 